Tetra Bio Pharma Inc (OTCMKTS:TBPMF) Gets Accurate Results From Patients in The Primary End-Point Of Serenity Clinical Study: Launches A Study To Determine CBD Metabolites

Tetra Bio Pharma Inc (OTCMKTS:TBPMF) has reported results of the survey conducted on the patients, who are suffering from cancer, in the US and Canada. The cancer patients are administered CAUMZ orally and measured their responses in the SERENITY Clinical study. Tetra is pleased to achieve the primary endpoint of the SERENITY clinical trial.

50% to 80% of cancer patients experience cachexia

Around 50% to 80% of the cancer patients suffer from progressive functional impairment because of the loss of skeletal muscle mass. The multifactorial syndrome is called cachexia. Intense symptoms reported in cancer patients with cachexia are lack of proper sleep, wellbeing, appetite, fatigue and increased pain. Secondary symptoms in those patients are depression, nausea, and pain. It reduces the intake of calories. Cancer patients with cachexia could not regain skeletal muscle mass despite providing nutritional support.

Survey on patients in the US and Canada

Tetra has surveyed 33 cancer patients in the US and Canada during February and March 2020. It has obtained feedback from the patients and physicians. The company has delivered similar questionnaires to the patients and physicians but with different instructions for each group.

66.7% of the patients in the survey reported pain whereas 57.6% have experienced fatigue. Around 45.5% of the patients experienced a lack of appetite. The principal and co-principal investigators in the SERENITY clinical study said patients with cancer and cachexia experienced pain (88.9%), lack of appetite (72.2%), fatigue (83.3%), nausea (61.1%), weight loss (55.6%), and difficulty in sleeping (33.3%). They also said the patients experienced distressing functional impacts during the study.

Chief Regulatory Officer and CEO of Tetra, Dr. Guy Chamberland said the survey results further strengthened the understanding of symptoms faced by advanced cancer patients with cachexia. Therefore, the feedback from physicians and patients strengthens its belief that Caumz will provide significant benefits to the patients.

Launches a study to determine levels of cannabinoid metabolites

Tetra has launched a study to determine the levels of cannabinoid metabolites, CBN, and CBGA in the plasma levels of humans, who are administered QIXLEEF. The company can analyze the human plasma samples and understand how CBD and THC are degraded in humans. It also helps to understand how long these compounds will remain in the blood.